US Broker Ratings

Twist Bioscience Corporation (TWST) Stock Analysis: Exploring a Potential 16.61% Upside in the Synthetic DNA Market

Twist Bioscience Corporation (NASDAQ: TWST), a frontrunner in the synthetic DNA landscape, presents an intriguing opportunity for investors with a potential upside of 16.61%, as indicated by its average analyst..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Strong Buy Ratings Signal 42.62% Upside Potential

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical trailblazer in the healthcare sector, is capturing investor attention with its focus on rare and orphan diseases. With a market capitalization of $5.3..

Progyny, Inc. (PGNY) Stock Analysis: Exploring a 61.78% Potential Upside in the Healthcare Sector

Progyny, Inc. (PGNY), a prominent player in the healthcare sector specializing in fertility benefits management, has been capturing investor attention with its promising potential upside of 61.78%. As a company..

Structure Therapeutics Inc. (GPCR) Stock Analysis: Exploring a 148% Potential Upside

Structure Therapeutics Inc. (NASDAQ: GPCR) is attracting considerable attention in the biotechnology sector, primarily due to its promising pipeline focused on chronic diseases with unmet medical needs. As a clinical-stage..

ACADIA Pharmaceuticals (ACAD) Stock Analysis: Exploring a 51% Potential Upside

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a prominent player in the biotechnology industry, is capturing investor attention with its promising portfolio in the healthcare sector. The San Diego-based company, with a..

Liquidia Corporation (LQDA) Stock Analysis: Evaluating a 44% Potential Upside in Biopharmaceutical Innovator

Liquidia Corporation (NASDAQ: LQDA), a promising player in the biopharmaceutical sector, is capturing investor attention with its innovative approach to treating rare cardiopulmonary diseases. With a market capitalization of $3.1..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A Promising 245% Upside in the Biotech Arena

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a notable player in the biotechnology sector, has been capturing investor interest with its innovative approach to treating severe allergic reactions. Headquartered in San Diego,..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a Potential 251% Upside

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a prominent player in the biotechnology sector, is drawing investor attention with an enticing potential upside of 251.35%. With its focus on innovative treatments for..

Celldex Therapeutics (CLDX) Stock Analysis: A Biotech Gem with 84% Upside Potential

For investors seeking a foothold in the biotechnology sector, Celldex Therapeutics, Inc. (NASDAQ: CLDX) presents a compelling opportunity. With a market capitalization of $1.96 billion, Celldex is positioned at the..

Novavax, Inc. (NVAX) Investor Outlook: Potential Upside of Over 70% with Growing Revenue

Novavax, Inc. (NASDAQ: NVAX), a prominent player in the biotechnology sector, has recently captured investor attention with its substantial potential upside of 70.31%. As a company devoted to the discovery,..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: A Biotech Contender with 42% Upside Potential

In the ever-evolving landscape of biotechnology, Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) stands out as a promising player, particularly in the field of eye care. With a market capitalization of $2.85..

Janux Therapeutics, Inc. (JANX) Stock Analysis: Unpacking a 314% Potential Upside Amid Breakthrough Cancer Therapies

Janux Therapeutics, Inc. (NASDAQ: JANX), a trailblazing entity in the biotechnology sector, is capturing investor attention with its innovative approach to cancer treatment. Headquartered in San Diego, California, Janux focuses..

Kiniksa Pharmaceuticals (KNSA): Growth Potential with 25.55% Upside and Strong Buy Ratings

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) has emerged as a noteworthy player in the healthcare sector, particularly in the niche of specialty and generic drug manufacturing. With a market capitalization..

ANI Pharmaceuticals, Inc. (ANIP)

⚠️ No article content returned.

..

Guardian Pharmacy Services, Inc (GRDN): Investor Outlook and Growth Prospects with a Potential 6.31% Upside

Guardian Pharmacy Services, Inc. (NASDAQ: GRDN) has emerged as a noteworthy player in the healthcare sector, focusing on medical care facilities across the United States. With a market capitalization of..

Neogen Corporation (NEOG) Stock Analysis: Navigating a 30.94% Potential Upside Amidst Challenges

Neogen Corporation (NEOG), a key player in the healthcare sector, particularly within the medical devices industry, is currently drawing attention from investors due to its intriguing potential upside of 30.94%...

Apellis Pharmaceuticals (APLS) Investor Outlook: Navigating Potential Upside in a Volatile Biotech Market

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a noteworthy player in the biotechnology sector, drawing investors’ attention with its focus on developing novel therapies for diseases with significant unmet needs. Headquartered..

National HealthCare Corporation (NHC) Stock Analysis: Navigating the Healthcare Sector with a Solid Revenue Growth

National HealthCare Corporation (NYSE: NHC) stands as a significant player in the healthcare industry, primarily focusing on medical care facilities across the United States. With a market capitalization of $2.52..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Evaluating the 12.56% Potential Upside

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stands as a compelling entity in the biotechnology sector, capturing investor attention with its innovative pipeline and a notable potential upside of 12.56%, according to..

CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring an 87.97% Potential Upside

CRISPR Therapeutics AG (NASDAQ: CRSP), a pioneering company in the field of gene editing, is capturing the attention of investors with its robust pipeline of innovative therapies and a significant..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds